Kemin Receives Anvisa Approval for Immune-strengthening Dietary Supplement BetaVia(TM)

Brazil's Health Regulatory Agency approves product as novel ingredient

DES MOINES, lowa, Dec. 7, 2020 /PRNewswire/ -- Kemin Industries, a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services, announced today that its human nutrition and health product for immune support, BetaVia $^{\text{TM}}$, has received approval as a novel ingredient in Brazil.

On November 9, the Health Regulatory Agency (Anvisa) of the Brazilian Ministry of Health published a resolution[1] authorizing BetaVia for use as a new food ingredient in the country. This authorization in Brazil follows a recent positive safety evaluation conducted by the European Food Safety Authority (EFSA) on BetaVia, as well as BetaVia's Generally Recognized as Safe (GRAS) self-affirmed status from the U.S. Food and Drug Administration.

"We are extremely excited to learn of Anvisa's approval of BetaVia, as Brazil is a key strategic market in terms of growth for the product and Kemin Human Nutrition and Health," said José Piccolotto, President, Kemin Human Nutrition and Health. "Brazil is one of many countries showing a desire to provide immune-enhancing ingredients in its functional food and beverages and dietary supplements, and our ingredients – including BetaVia – meet this need."

BetaVia is manufactured through a patented fermentation process using a proprietary strain of the algae *Euglena gracilis*. The finished product offers beneficial immunomodulatory effects that are supported by clinical and preclinical research.

A recently published clinical trial² showed that participants who received a supplement containing BetaVia Complete for a 90-day period experienced the following immune-health benefits when compared to those participants who received a placebo:

- 30 fewer upper respiratory tract infection (URTI) symptoms, which is 70% less than those receiving the placebo
- 10 fewer URTI symptom days
- 45% fewer URTI episodes
- 3.3 fewer self-reported sick days
- 80% lower global severity, which is the total severity of symptoms over time

"Kemin is focused on delivering high-quality, sustainable solutions to our customers, and we look forward to meeting the growing immune health needs within the Brazilian market," said Rosemeire Shiraishi, Sales Manager – Latin America, Kemin Human Nutrition and Health.

To learn more about the immune-health benefits of BetaVia[™] click here.

About Kemin Industries

Kemin Industries (www.kemin.com) is a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services. The company supplies over 500 specialty ingredients for human and animal health and nutrition, pet food, aquaculture, nutraceutical, food technologies, crop technologies and textile industries.

For over half a century, Kemin has been dedicated to using applied science to address industry challenges and offer product solutions to customers in more than 120 countries. Kemin provides ingredients to feed a growing population with its commitment to the quality, safety and efficacy of food, feed and health-related products.

Established in 1961, Kemin is a privately held, family-owned-and-operated company with more than 2,800 global employees and operations in 90 countries, including manufacturing facilities in Belgium, Brazil, China, India, Italy, Russia, San Marino, Singapore, South Africa and the United States.

Media Contacts:

Kim Edwards, Global Product Manager, Kim.Edwards@kemin.com, +1 515 559 5407 Wládia Vilar, Technical Services Manager, Wladia.Vilar@kemin.com, +55 19 98356-0039

REFERENCES:

 $https://news.kemin.com/2020-12-07-Kemin-Receives-Anvisa-Approval-for-Immune-strengthening-Dietary-Supplement-BetaVia-TM?locale=ru_ru$

^[1]Resolução-Re Nº 4.502, De 4 De Novembro De 2020

² Evans, M., et al., Effect of a Euglena gracilis Fermentate on Immune Function in Healthy, Active Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients, 2019, 11(12), 2926